ijms-logo

Journal Browser

Journal Browser

Anti-Cancer Effects of Natural Products: 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pharmacology".

Deadline for manuscript submissions: 20 June 2026 | Viewed by 664

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pathology, College of Korean Medicine, Kyung Hee University, Seoul 02447, Republic of Korea
Interests: cancer; redox; endocrinology; herbal medicine; pathology; cancer stem cell; cancer reprogramming; miRNA; alternative splicing factor; drug resistance; drug development; drug delivery system
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Since the 1940s, when the first cancer treatment was developed, cancer has remained incurable. Even though complete recovery is only possible for a few early cancers, metastasis and the recurrence of cancer render treatment impossible and account for the vast majority of cancer-related fatalities. Since then, cancer-specific targeted anticancer medications have been developed to treat a wide range of cancers; however, limitations such as resistance mechanisms and adverse effects remain. Seventy-five percent of anti-cancer drugs are derived from herbal components. More than fifty percent of today's pharmaceuticals are derived from natural products. Presently, the most significant research emphasizes the need for multiple mechanism studies to identify novel biomarkers of the resistance mechanism using herbal ingredients in the prevention and treatment of various malignancies.

Dr. Moon Nyeo Park
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • natural products
  • herbal medicine
  • anticancer therapies
  • metastasis
  • recurrence
  • resistance mechanism
  • novel biomarker

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

19 pages, 10282 KB  
Article
Palmaturbine Inhibits Pancreatic Ductal Adenocarcinoma by Suppressing the JAK2/STAT3 Signaling Pathway
by Hong-Zhang Shen, Li-Yun Zheng, Dong-Chao Xu and Yu-Lian Wu
Int. J. Mol. Sci. 2026, 27(4), 1707; https://doi.org/10.3390/ijms27041707 - 10 Feb 2026
Viewed by 376
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an extremely poor prognosis, and current clinical treatment options are limited. Natural products, due to their multi-target and low-toxicity characteristics, have emerged as an important direction for the development of anti-tumor drugs. Palmaturbine [...] Read more.
Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an extremely poor prognosis, and current clinical treatment options are limited. Natural products, due to their multi-target and low-toxicity characteristics, have emerged as an important direction for the development of anti-tumor drugs. Palmaturbine (Pal), an isoquinoline alkaloid derived from Coptis chinensis and Berberis species, has shown anti-inflammatory and anti-tumor potential in preliminary studies; however, its mechanism of action in PDAC remains unclear. This study systematically evaluated the anti-tumor effects and molecular mechanisms of Pal on PDAC through in vitro and in vivo experiments. In vitro, Pal significantly inhibited PDAC cell proliferation, migration, and invasion, induced G2/M phase cell cycle arrest, and promoted apoptosis. Transcriptomic sequencing and Western blot analysis revealed that Pal suppressed the JAK2/STAT3 signaling pathway by inhibiting the phosphorylation of JAK2 and STAT3. Animal experiments further indicated that Pal significantly inhibited the growth of subcutaneous xenograft tumors in nude mice without causing obvious toxicity. In summary, Pal, as a natural JAK/STAT pathway inhibitor, exhibits favorable anti-tumor activity and safety in PDAC treatment, holding potential as a novel candidate drug for PDAC. Full article
(This article belongs to the Special Issue Anti-Cancer Effects of Natural Products: 2nd Edition)
Show Figures

Figure 1

Back to TopTop